Docket #: S21-138
Advancing CAR-T Cell Therapies with Memory-Like Traits
Researchers at Stanford University have discovered a way to enhance the effectiveness of CAR-T cell therapeutics through inducing a more memory-like phenotype.
Chimeric Antigen Receptor (CAR) T-cell therapies represent a burgeoning field of immunotherapy, enabling the customization of a patient's immune system to combat tumor cells. However, current iterations of CAR-T cell therapies face limitations in achieving enduring remission against various liquid and solid tumors, primarily stemming from issues like inadequate persistence and the development of T cell exhaustion.
In order to enhance CAR T cell efficacy, researchers from Crystal Mackall's group have identified the transcription factor FOXO1 as critical to CAR T cell antitumor potency. Furthermore, they find that overexpression of FOXO1 mediates a memory-like phenotype in CAR T cells, thus identifying an axis through which CAR T cells can be modulated to prevent the development of exhaustion, promote persistence, and enhance adoptive cell therapy in the fight against cancer.
Stage of Development
Research:
In vivo
Applications
- CAR-T therapeutics
- TIL therapeutics
- TCR T-cell therapeutics
- Therapeutics for liquid tumors
- Therapeutics for solid tumors
Advantages
- Longer remission from solid and liquid cancers
- Less T-cell exhaustion
- Better persistence of T-cell therapeutics
Publications
- Doan, A.E., Mueller, K.P., Chen, A.Y. et al. (2024). FOXO1 is a master regulator of memory programming in CAR T cells. Nature.
Related Links
Patents
- Published Application: WO2023212566
Similar Technologies
-
Infrared Nanoprobes: Advancing Cancer Vaccines and Real-Time In Vivo Immune Response Insights S22-397Infrared Nanoprobes: Advancing Cancer Vaccines and Real-Time In Vivo Immune Response Insights
-
Screening for Gene Modifications to Improve T Cell Function S21-195Screening for Gene Modifications to Improve T Cell Function
-
Optimizing clonal expansion of CD8 T cells by using silent mutations S22-077Optimizing clonal expansion of CD8 T cells by using silent mutations